{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:34:08Z","timestamp":1773293648652,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["PP-1901-33100"],"award-info":[{"award-number":["PP-1901-33100"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fatigue is highly prevalent in adults with multiple sclerosis (MS) and current treatments offer limited benefit. It has been speculated that placebos only have an effect when they are administered with deception and concealment, which is unethical in clinical practice. Recent studies suggest that ethically informed, open-label placebos (OLP) can produce symptomatic benefits. As such, we primarily sought to investigate the feasibility and secondarily assess the preliminary effects of OLP to treat MS fatigue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Feasibility outcomes including accrual, retention, and OLP adherence estimates were assessed in this 21-day assessor blinded, RCT. We compared results of assignment to three conditions: (1) OLP with a positive expectancy for beneficial effects along with the prescription to take 2 placebo pills twice a day (OLP), (2) positive expectancy (EXP) for beneficial placebo effects, or (3) a usual care only (UCO). We considered the study to be feasible if progression criteria, including the enrollment target of 48 participants, retention target of\u2009&gt;\u200980% participants, and OLP adherence target of\u2009&gt;\u200990%, were met. As secondary analyses, we provide descriptive statistics and crude linear mixed models (LMM) based estimates to assess the change in fatigue (assessed via Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS)) at days 21, 28, and 35 versus baseline with corresponding 95%, 85%, and 75% confidence intervals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>One-hundred and eight adults with MS were screened of which 48 were randomized (16 per group). Retention rate was 98% with one participant being lost to follow-up. Placebo adherence was over 90%. At day 21, 7 of 9 (78%) randomized to OLP considered prescribing placebos to treat fatigue as \u201cmoderately-to-completely\u201d acceptable. Next, the LMM based change in FSS mean score at day 21 with respect to baseline in the OLP and EXP group versus UCO group was about 0.6 units lower (95% CI:\u2009\u2212\u20091.206,\u2009\u2212\u20090.003;\u2009\u2212\u20091.301,\u2009\u2212\u20090.065, respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>OLP was deemed feasible and acceptable by most participants and there was mild evidence that, compared to UCO, it may reduce fatigue severity in adults with MS. Larger trials of OLP are required to determine whether OLP might be a viable treatment for MS fatigue.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration number<\/jats:title>\n            <jats:p>NCT04002102 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/show\/NCT04002102\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/show\/NCT04002102<\/jats:ext-link>, 2019); registered 30 September 2019.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40814-025-01674-w","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:02:41Z","timestamp":1751544161000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Open label placebo to treat fatigue in people with multiple sclerosis: feasibility and preliminary effects"],"prefix":"10.1186","volume":"11","author":[{"given":"Navneet Kaur","family":"Baidwan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Ying","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanjila","family":"Nawshin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teri","family":"Hoenemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Riser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Motl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapan","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"2","key":"1674_CR1","doi-asserted-by":"publisher","first-page":"e0115541","DOI":"10.1371\/journal.pone.0115541","volume":"10","author":"TJ Weiland","year":"2015","unstructured":"Weiland TJ, Jelinek GA, Marck CH, Hadgkiss EJ, van der Meer DM, Pereira NG, et al. Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet. PLoS ONE. 2015;10(2):e0115541.","journal-title":"PLoS ONE"},{"key":"1674_CR2","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jns.2017.07.042","volume":"380","author":"TT Yang","year":"2017","unstructured":"Yang TT, Wang L, Deng XY, Yu G. Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;380:256\u201361.","journal-title":"J Neurol Sci"},{"issue":"1","key":"1674_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1545968306298934","volume":"22","author":"D Kos","year":"2008","unstructured":"Kos D, Kerckhofs E, Nagels G, D\u2019Hooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair. 2008;22(1):91\u2013100.","journal-title":"Neurorehabil Neural Repair"},{"issue":"3","key":"1674_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/135245850000600308","volume":"6","author":"R Bakshi","year":"2000","unstructured":"Bakshi R, Shaikh ZA, Miletich RS, Czarnecki D, Dmochowski J, Henschel K, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler. 2000;6(3):181\u20135.","journal-title":"Mult Scler"},{"issue":"1","key":"1674_CR5","doi-asserted-by":"publisher","first-page":"31682","DOI":"10.1038\/s41598-024-80992-0","volume":"14","author":"D Machtoub","year":"2024","unstructured":"Machtoub D, Fares C, Sinan H, Al Hariri M, Nehme R, Chami J, et al. Factors affecting fatigue progression in multiple sclerosis patients. Sci Rep. 2024;14(1):31682.","journal-title":"Sci Rep"},{"issue":"8","key":"1674_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/sleep\/33.8.1061","volume":"33","author":"TJ Braley","year":"2010","unstructured":"Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061\u20137.","journal-title":"Sleep"},{"key":"1674_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.msard.2017.10.011","volume":"19","author":"H Shangyan","year":"2018","unstructured":"Shangyan H, Kuiqing L, Yumin X, Jie C, Weixiong L. Meta-analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. Mult Scler Relat Disord. 2018;19:85\u20139.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"1674_CR8","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13063-017-1964-x","volume":"18","author":"S Ballou","year":"2017","unstructured":"Ballou S, Kaptchuk TJ, Hirsch W, Nee J, Iturrino J, Hall KT, et al. Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial. Trials. 2017;18(1):234.","journal-title":"Trials"},{"key":"1674_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/archpsyc.1965.01720340008002","volume":"12","author":"LC Park","year":"1965","unstructured":"Park LC, Covi L. Nonblind placebo trial: an exploration of neurotic patients\u2019 responses to placebo when its inert content is disclosed. Arch Gen Psychiatry. 1965;12:36\u201345.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"1674_CR10","doi-asserted-by":"publisher","first-page":"e15591","DOI":"10.1371\/journal.pone.0015591","volume":"5","author":"TJ Kaptchuk","year":"2010","unstructured":"Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, et al. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS ONE. 2010;5(12):e15591.","journal-title":"PLoS ONE"},{"key":"1674_CR11","doi-asserted-by":"crossref","unstructured":"Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014;6(218):218ra5.","DOI":"10.1126\/scitranslmed.3006175"},{"issue":"12","key":"1674_CR12","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1097\/j.pain.0000000000001683","volume":"160","author":"J Kleine-Borgmann","year":"2019","unstructured":"Kleine-Borgmann J, Schmidt K, Hellmann A, Bingel U. Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial. Pain. 2019;160(12):2891\u20137.","journal-title":"Pain"},{"issue":"12","key":"1674_CR13","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1097\/j.pain.0000000000000700","volume":"157","author":"C Carvalho","year":"2016","unstructured":"Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016;157(12):2766\u201372.","journal-title":"Pain"},{"issue":"6","key":"1674_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000447242","volume":"85","author":"M Schaefer","year":"2016","unstructured":"Schaefer M, Harke R, Denke C. Open-label placebos improve symptoms in allergic rhinitis: a randomized controlled trial. Psychother Psychosom. 2016;85(6):373\u20134.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"1674_CR15","doi-asserted-by":"publisher","first-page":"20090","DOI":"10.1038\/s41598-020-77255-z","volume":"10","author":"Y Pan","year":"2020","unstructured":"Pan Y, Meister R, L\u00f6we B, Kaptchuk TJ, Buhling KJ, Nestoriuc Y. Open-label placebos for menopausal hot flushes: a randomized controlled trial. Sci Rep. 2020;10(1):20090.","journal-title":"Sci Rep"},{"issue":"6","key":"1674_CR16","first-page":"407","volume":"30","author":"C Blease","year":"2016","unstructured":"Blease C, Colloca L, Kaptchuk TJ. Are open-label placebos ethical? Informed consent and ethical equivocations Bioethics. 2016;30(6):407\u201314.","journal-title":"Informed consent and ethical equivocations Bioethics"},{"issue":"1","key":"1674_CR17","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1038\/s41598-018-20993-y","volume":"8","author":"TW Hoenemeyer","year":"2018","unstructured":"Hoenemeyer TW, Kaptchuk TJ, Mehta TS, Fontaine KR. Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial. Sci Rep. 2018;8(1):2784.","journal-title":"Sci Rep"},{"issue":"6","key":"1674_CR18","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00520-018-4477-6","volume":"27","author":"ES Zhou","year":"2019","unstructured":"Zhou ES, Hall KT, Michaud AL, Blackmon JE, Partridge AH, Recklitis CJ. Open-label placebo reduces fatigue in cancer survivors: a randomized trial. Support Care Cancer. 2019;27(6):2179\u201387.","journal-title":"Support Care Cancer"},{"issue":"12","key":"1674_CR19","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/oncolo\/oyac184","volume":"27","author":"S Yennurajalingam","year":"2022","unstructured":"Yennurajalingam S, Azhar A, Lu Z, Rodriguez AJ, Arechiga AB, Guerra-Sanchez M, et al. Open-label placebo for the treatment of cancer-related fatigue in patients with advanced cancer: a randomized controlled trial. Oncologist. 2022;27(12):1081\u20139.","journal-title":"Oncologist"},{"issue":"3","key":"1674_CR20","doi-asserted-by":"publisher","first-page":"e0150205","DOI":"10.1371\/journal.pone.0150205","volume":"11","author":"SM Eldridge","year":"2016","unstructured":"Eldridge SM, Lancaster GA, Campbell MJ, Thabane L, Hopewell S, Coleman CL, et al. Defining feasibility and pilot studies in preparation for randomised controlled trials: development of a conceptual framework. PLoS ONE. 2016;11(3):e0150205.","journal-title":"PLoS ONE"},{"key":"1674_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1471-2288-14-41","volume":"14","author":"EC Lee","year":"2014","unstructured":"Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation of pilot trials: should significance thresholds be reconsidered? BMC Med Res Methodol. 2014;14:41.","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"1674_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1001\/jamapediatrics.2021.5750","volume":"176","author":"S Nurko","year":"2022","unstructured":"Nurko S, Saps M, Kossowsky J, Zion SR, Di Lorenzo C, Vaz K, et al. Effect of open-label placebo on children and adolescents with functional abdominal pain or irritable bowel syndrome: a randomized clinical trial. JAMA Pediatr. 2022;176(4):349\u201356.","journal-title":"JAMA Pediatr"},{"issue":"1\u20132","key":"1674_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jns.2013.05.023","volume":"331","author":"YC Learmonth","year":"2013","unstructured":"Learmonth YC, Dlugonski D, Pilutti LA, Sandroff BM, Klaren R, Motl RW. Psychometric properties of the Fatigue Severity Scale and the Modified Fatigue Impact Scale. J Neurol Sci. 2013;331(1\u20132):102\u20137.","journal-title":"J Neurol Sci"},{"key":"1674_CR24","doi-asserted-by":"crossref","unstructured":"SA J. Sample size of 12 per group rule ofthumb for a pilot study. Pharmaceutical statistics. 2005;4(4):287\u201391.","DOI":"10.1002\/pst.185"},{"issue":"3","key":"1674_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jclinepi.2011.07.011","volume":"65","author":"J Sim","year":"2012","unstructured":"Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol. 2012;65(3):301\u20138.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"1674_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/0962280215588241","volume":"25","author":"AL Whitehead","year":"2016","unstructured":"Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057\u201373.","journal-title":"Stat Methods Med Res"},{"key":"1674_CR27","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1745-6215-15-264","volume":"15","author":"MD Teare","year":"2014","unstructured":"Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials. 2014;15:264.","journal-title":"Trials"},{"issue":"10","key":"1674_CR28","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121\u20133.","journal-title":"Arch Neurol."},{"issue":"2","key":"1674_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1191\/1352458505ms1148oa","volume":"11","author":"N T\u00e9llez","year":"2005","unstructured":"T\u00e9llez N, R\u00edo J, Tintor\u00e9 M, Nos C, Gal\u00e1n I, Montalban X. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler. 2005;11(2):198\u2013202.","journal-title":"Mult Scler"},{"issue":"8","key":"1674_CR30","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.5664\/jcsm.7258","volume":"14","author":"BR Lapin","year":"2018","unstructured":"Lapin BR, Bena JF, Walia HK, Moul DE. The Epworth Sleepiness Scale: validation of one-dimensional factor structure in a large clinical sample. J Clin Sleep Med. 2018;14(8):1293\u2013301.","journal-title":"J Clin Sleep Med"},{"issue":"5","key":"1674_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343.","journal-title":"Ann Med"},{"issue":"2","key":"1674_CR32","doi-asserted-by":"publisher","first-page":"604","DOI":"10.2466\/03.27.PMS.120v19x7","volume":"120","author":"S Amireault","year":"2015","unstructured":"Amireault S, Godin G. The Godin-Shephard leisure-time physical activity questionnaire: validity evidence supporting its use for classifying healthy adults into active and insufficiently active categories. Percept Mot Skills. 2015;120(2):604\u201322.","journal-title":"Percept Mot Skills"},{"issue":"4","key":"1674_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.7224\/1537-2073.2015-028","volume":"18","author":"LB Strober","year":"2016","unstructured":"Strober LB, Binder A, Nikelshpur OM, Chiaravalloti N, DeLuca J. The Perceived Deficits Questionnaire: perception, deficit, or distress? Int J MS Care. 2016;18(4):183\u201390.","journal-title":"Int J MS Care"},{"issue":"1","key":"1674_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-020-0181-7","volume":"4","author":"NE Rothrock","year":"2020","unstructured":"Rothrock NE, Amtmann D, Cook KF. Development and validation of an interpretive guide for PROMIS scores. J Patient Rep Outcomes. 2020;4(1):16.","journal-title":"J Patient Rep Outcomes"},{"issue":"19","key":"1674_CR35","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.2106\/JBJS.O.00030","volume":"97","author":"NC Laucis","year":"2015","unstructured":"Laucis NC, Hays RD, Bhattacharyya T. Scoring the SF-36 in orthopaedics: a brief guide. J Bone Joint Surg Am. 2015;97(19):1628\u201334.","journal-title":"J Bone Joint Surg Am"},{"key":"1674_CR36","unstructured":"Fox J. Applied regression analysis and generalized linear models.\u00a0Thousand Oaks, California: Sage; 2015."},{"key":"1674_CR37","unstructured":"SAS (SAS Institute, Inc.). 2004. p. SAS\/STAT\u00ae 9.4: user\u2019s guide."},{"issue":"11","key":"1674_CR38","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jpain.2021.05.001","volume":"22","author":"MH Bernstein","year":"2021","unstructured":"Bernstein MH, Fuchs N, Rosenfield M, Weiss AP, Blease C, Locher C, et al. Treating pain with open-label placebos: a qualitative study with post-surgical pain patients. J Pain. 2021;22(11):1518\u201329.","journal-title":"J Pain"},{"key":"1674_CR39","doi-asserted-by":"publisher","first-page":"f3757","DOI":"10.1136\/bmj.f3757","volume":"347","author":"SC Hull","year":"2013","unstructured":"Hull SC, Colloca L, Avins A, Gordon NP, Somkin CP, Kaptchuk TJ, et al. Patients\u2019 attitudes about the use of placebo treatments: telephone survey. BMJ. 2013;347:f3757.","journal-title":"BMJ"}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-025-01674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-025-01674-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-025-01674-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:02:45Z","timestamp":1751544165000},"score":1,"resource":{"primary":{"URL":"https:\/\/pilotfeasibilitystudies.biomedcentral.com\/articles\/10.1186\/s40814-025-01674-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1186\/s40814-025-01674-w","relation":{},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board (IRB) of the University of Alabama at Birmingham (UAB) approved this study, and written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A, only aggregate level data are presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}